Late news: US FTC gives J&J (Johnson & Johnson) conditional approval for Guidant acquisition
This article was originally published in Clinica
Executive Summary
Ending weeks of mounting anticipation, the US Federal Trade Commission (FTC) has finally given Johnson & Johnson conditional approval to go ahead with its proposed $25.4bn acquisition of Guidant - only for the healthcare group to state openly that it is now having second thoughts about going through with the deal.